Inclusion Criteria:

• Age ≥ 18 years old; AND
• Were treated with curative intent; AND
• Are planning to undergo regular follow-up and monitoring for cancer recurrence per standard of care at the enrolling site; AND
• Provided written informed consent to participate in the study; AND
• Are willing to have de-identified clinical data shared with investigators at regular intervals as outlined in the study protocol and informed consent; AND
• Are willing to provide blood samples at enrollment and at subsequent clinical visits coinciding with standard of care follow-up, for up to 5 years as outlined in the study protocol and informed consent; AND
• Have at least one blood sample collected 4-12 weeks after completion of primary treatment of the Index Cancer.
• Have a histologically confirmed Index Cancer that qualifies for inclusion, defined as:

Primary Study Cohorts:

• Cohort 1: Muscle invasive carcinoma of the bladder, ureter, or renal pelvis (stage II-III).
• Cohort 2: Non-small cell lung cancer (stage II-III).
• Cohort 3: Invasive breast carcinoma with all of the following:
  • Clinical stage T1-4/N0-3/M0 at presentation; AND
  • Completed preoperative systemic chemotherapy-containing regimen; AND
  • Underwent definitive surgical resection of the primary tumor; AND
  • Has pathological evidence of residual invasive carcinoma in the breast and/or axillary lymph nodes; AND
  • Hormone receptor and HER2 status are known.

Exploratory Cohorts:

• Cohort 4: Stage IIb-III cutaneous melanoma or limited (resectable) stage IV melanoma treated with curative intent.
• Cohort 5: Esophageal or gastroesophageal junction carcinoma (stage II-III).
• Cohort 6: Gastric adenocarcinoma (stage II-III).
• Cohort 7: Surgically resected pancreatic adenocarcinoma.
• Cohort 8: Invasive squamous cell carcinoma of the head and neck (includes stage I-III oral cavity, oropharynx, hypopharynx, larynx, nasopharynx, nasal cavity, paranasal sinus, and salivary gland cancers).
• Cohort 9: High-risk epithelial ovarian or Fallopian tube carcinoma (defined as stage IC-III or stage I that has high grade (grade 3-4) or clear cell histology).
• Cohort 10: High-risk endometrial carcinoma (defined as having any of the following: serous or clear cell adenocarcinoma histology (any stage), grade 3 or 4 deeply invasive (T1b or greater) endometrioid carcinoma, stage III disease (any histology)).
• Cohort 11: High-risk renal cell carcinoma (defined as high grade (grade 3-4) stage II, stage III or limited (resectable) stage IV treated with curative intent).
• For the purposes of this study, participants receiving extended (> 6 months planned duration) non-chemotherapy systemic treatment will be considered in their end of primary treatment phase after the initial planned surgery, chemotherapy and/or radiation.
• Determination of stage for eligibility assessment and enrollment should be based on pathologic stage unless the participant received pre-surgical/neoadjuvant therapy, in which case standard pre-treatment clinical staging will be used to determine eligibility.

Exclusion Criteria:

• History of allogeneic organ or tissue transplant.
• Index cancer has neuroendocrine histology.
• History of another primary cancer, with the exception of the following (if adequately treated and the patient is without evidence of disease at the time of enrollment): in situ cancers, non-melanoma skin carcinoma, localized low-risk prostate cancer (Gleason score < 6) with PSA in the normal range, and stage I papillary thyroid carcinoma.
• Known distant metastasis at time of enrollment (with the exception of participants with limited/resectable stage IV cutaneous melanoma or RCC).
• Is participating in a clinical trial or another observational study that is evaluating the performance of another genomic test in the post-treatment surveillance setting at predicting/detecting recurrence.

Eligibility last updated 11/3/21. Questions regarding updates should be directed to the study team contact.